189 related articles for article (PubMed ID: 20839259)
21. A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis.
Benincasa E; Conti A; Bossone G; Gallà DA; Gianciotta A; Zuccaro SM; Madaio R
Tumori; 2009; 95(3):403. PubMed ID: 19688987
[No Abstract] [Full Text] [Related]
22. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
[TBL] [Abstract][Full Text] [Related]
25. Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Tomita Y
Int J Urol; 2010 Sep; 17(9):815-6. PubMed ID: 20727052
[No Abstract] [Full Text] [Related]
26. Randomized discontinuation trial of sorafenib (BAY 43-9006).
Jain L; Venitz J; Figg WD
Cancer Biol Ther; 2006 Oct; 5(10):1270-2. PubMed ID: 16969070
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
[TBL] [Abstract][Full Text] [Related]
28. Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B
Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637
[TBL] [Abstract][Full Text] [Related]
29. Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Wu Y; Zhao Y
Int J Urol; 2011 Jun; 18(6):430-1. PubMed ID: 21599760
[No Abstract] [Full Text] [Related]
30. Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Procopio G
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1689-92. PubMed ID: 22050017
[TBL] [Abstract][Full Text] [Related]
31. Speeding up cancer-drug development.
Burton A
Lancet Oncol; 2006 Oct; 7(10):798. PubMed ID: 17039633
[No Abstract] [Full Text] [Related]
32. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
[TBL] [Abstract][Full Text] [Related]
34. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
Kasibhatla M; Steinberg P; Meyer J; Ernstoff MS; George DJ
Clin Genitourin Cancer; 2007 Mar; 5(4):291-4. PubMed ID: 17553211
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
36. Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
Takeda H; Nakano Y; Kashiwagi Y; Yoshino Y; Gotoh M
Urol Int; 2012; 88(2):235-7. PubMed ID: 22179282
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib for the treatment of renal cancer.
Strumberg D
Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
[TBL] [Abstract][Full Text] [Related]
38. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Siddiqui SA; Frigola X; Bonne-Annee S; Mercader M; Kuntz SM; Krambeck AE; Sengupta S; Dong H; Cheville JC; Lohse CM; Krco CJ; Webster WS; Leibovich BC; Blute ML; Knutson KL; Kwon ED
Clin Cancer Res; 2007 Apr; 13(7):2075-81. PubMed ID: 17404089
[TBL] [Abstract][Full Text] [Related]
39. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK
Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
